NHC
GSK icon

Nicholas Hoffman & Company’s GSK GSK Stock Holding History

Nicholas Hoffman & Company’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.97M Sell
37,580
-330
-0.9% -$17.5K 0.04% 95
2026
Q1 		$2.09M Sell
37,910
-7,040
-16% -$381K 0.05% 82
2025
Q4 		$2.2M Sell
44,950
-2,648
-6% -$124K 0.05% 77
2025
Q3 		$2.05M Sell
47,598
-35
-0.1% -$1.37K 0.05% 82
2025
Q2 		$1.83M Sell
47,633
-193
-0.4% -$7.38K 0.05% 84
2025
Q1 		$1.85M Buy
47,826
+650
+1% +$23.8K 0.07% 76
2024
Q4 		$1.6M Buy
47,176
+6,721
+17% +$242K 0.06% 85
2024
Q3 		$1.65M Sell
40,455
-1,032
-2% -$42.2K 0.07% 80
2024
Q2 		$1.6M Sell
41,487
-7
-0% -$294 0.07% 78
2024
Q1 		$1.78M Sell
41,494
-563
-1% -$23.2K 0.09% 70
2023
Q4 		$1.56M Sell
42,057
-1,139
-3% -$40.9K 0.09% 74
2023
Q3 		$1.57M Sell
43,196
-426
-1% -$15.1K 0.12% 71
2023
Q2 		$1.55M Sell
43,622
-478
-1% -$17.1K 0.06% 75
2023
Q1 		$1.57M Buy
44,100
+1,187
+3% +$41.5K 0.14% 74
2022
Q4 		$1.51M Sell
42,913
-1,178
-3% -$39.2K 0.16% 75
2022
Q3 		$1.3M Buy
44,091
+5,098
+13% +$193K 0.06% 79
2022
Q2 		$2.12M Buy
38,993
+483
+1% +$26.7K 0.1% 47
2022
Q1 		$2.1M Sell
38,510
-44
-0.1% -$2.39K 0.08% 51
2021
Q4 		$2.13M Sell
38,554
-865
-2% -$45K 0.07% 51
2021
Q3 		$1.88M Sell
39,419
-363
-0.9% -$18.2K 0.33% 53
2021
Q2 		$1.98M Buy
39,782
+460
+1% +$22.1K 0.36% 48
2021
Q1 		$1.75M Buy
39,322
+10,029
+34% +$455K 0.35% 50
2020
Q4 		$1.35M Buy
29,293
+5,873
+25% +$270K 0.31% 60
2020
Q3 		$1.1M Sell
23,420
-438
-2% -$21.9K 0.29% 64
2020
Q2 		$1.22M Sell
23,858
-1,989
-8% -$102K 0.35% 54
2020
Q1 		$1.22M Sell
25,847
-4,220
-14% -$225K 0.41% 54
2019
Q4 		$1.77M Sell
30,067
-281
-0.9% -$15.6K 0.49% 47
2019
Q3 		$1.62M Buy
30,348
+1,579
+5% +$81.2K 0.49% 47
2019
Q2 		$1.44M Sell
28,769
-552
-2% -$27.7K 0.45% 53
2019
Q1 		$1.53M Buy
29,321
+1,701
+6% +$85K 0.49% 49
2018
Q4 		$1.32M Sell
27,620
-7,110
-20% -$350K 0.45% 52
2018
Q3 		$1.74M Buy
34,730
+204
+0.6% +$10.4K 0.59% 36
2018
Q2 		$1.74M Sell
34,526
-479
-1% -$24.1K 0.64% 34
2018
Q1 		$1.71M Buy
35,005
+18,066
+107% +$841K 0.67% 33
2017
Q4 		$751K Sell
16,939
-9,199
-35% -$425K 0.29% 87
2017
Q3 		$1.33M Buy
26,138
+651
+3% +$33K 0.56% 50
2017
Q2 		$1.37M Buy
25,487
+998
+4% +$53.2K 0.62% 42
2017
Q1 		$1.29M Buy
24,489
+5,267
+27% +$267K 0.61% 48
2016
Q4 		$933K Sell
19,222
-2,334
-11% -$115K 0.47% 56
2016
Q3 		$1.16M Buy
21,556
+118
+0.6% +$6.47K 0.64% 40
2016
Q2 		$1.16M Buy
+21,438
New +$1.13M 0.67% 34

Other funds holding GSK

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.24B AUM 11.32% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
MHI
Miller Howard Investments Kingston, New York $3.77B AUM 23.82% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Nicholas Hoffman & Company's GSK Position: Q2 2026 in Review

Nicholas Hoffman & Company reduced its GSK (GSK) stake by 0.87% in Q2 2026, selling an estimated $17.5K and leaving 37,580 shares worth $1.97M. The position accounts for 0.04% of the portfolio, ranked #95.

Nicholas Hoffman & Company first reported a position in GSK in Q2 2016 and has held it in 41 quarters since. The position peaked at $2.2M in Q4 2025. 627 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Nicholas Hoffman & Company held 37,580 shares of GSK worth $1.97M as of Q2 2026.
  • Nicholas Hoffman & Company sold 330 GSK shares in Q2 2026, an estimated $17.5K.
  • GSK made up 0.04% of Nicholas Hoffman & Company's portfolio in Q2 2026, its #95 holding.
  • Nicholas Hoffman & Company first reported a position in GSK in Q2 2016 and has held it in 41 quarters since.
  • Nicholas Hoffman & Company's GSK position peaked at $2.2M in Q4 2025.
  • 627 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Nicholas Hoffman & Company's 13F filing for Q2 2026, filed 4 Aug 2026.